Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition. METHODS: We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8--with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11--every 21 days. Primary end points were the rate of clinical benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival. RESULTS: The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02). The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P=0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P=0.01). The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No significant difference was seen between the two groups in the rate of adverse events. CONCLUSIONS: The addition of iniparib to chemotherapy improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted. (Funded by BiPar Sciences [now owned by Sanofi-Aventis]; ClinicalTrials.gov number, NCT00540358.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oncology literature has indicated that positive phase II data are not necessarily replicated in the phase III setting”
In the citing paper
“Furthermore, ongoing clinical trials for metastatic TNBC are including platinum agents in their treatment regimens (4, 36–38).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [36]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Cited by
Items 401–500 of 876
Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Firoozbakht, F., Rezaeian, I., Rueda, L. G., & Ngom, A. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04662-6 · Cited by 26
Soung, Y. H., Kashyap, T., Nguyen, T., Yadav, G., Chang, H., Landesman, Y., & Chung, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17987 · Cited by 26
Resurrection of PARP Inhibitors in Breast Cancer
Lyons, T. G., & Robson, M. E. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7031 · Cited by 26
Kim, J. E., Ahn, H. J., Ahn, J. H., Yoon, D. H., Kim, S., Jung, K. H., Gong, G., Kim, M.-J., Son, B. H., & Ahn, S. H. (2012) · Journal of Breast Cancer · doi:10.4048/jbc.2012.15.2.197 · Cited by 26
Poly(ADP-ribose)polymerase (PARP) Inhibitors: From Bench to Bedside
Plummer, R. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.02.007 · Cited by 25
Molecular characteristics of recurrent triple-negative breast cancer
Tsai, C., Chiu, J., Yang, C., Wang, J., Tsai, Y., Tseng, L., CHEN, W.-S., & Shyr, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4360 · Cited by 25
miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype
Tommasi, S., Pinto, R., Danza, K., Pilato, B., Palumbo, O., Micale, L., & Summa, S. D. (2016) · Oncotarget · doi:10.18632/oncotarget.10345 · Cited by 25
BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer
Okuma, H. S., & Yonemori, K. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_13 · Cited by 25
Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer
Fojo, T., Amiri‐Kordestani, L., & Bates, S. E. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr386 · Cited by 25
Zhai, L., Li, S., Li, H., Zheng, Y., Lang, R., Fan, Y., Gu, F., Guo, X., Zhang, X., & Fu, L. (2015) · Europe PMC (PubMed Central) · Cited by 25
Domchek, S. M., Mitchell, G., Lindeman, G. J., Tung, N., Balmañà, J., Isakoff, S. J., Schmutzler, R. K., Audeh, M. W., Loman, N., Scott, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8134 · Cited by 25
von Minckwitz, G., Untch, M., & Loibl, S. (2012) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32835c0889 · Cited by 24
Fu, Z., Jiang, L., Zuo, Q.-M., Li, Z., Liu, Y., Wei, Z., & Cai, H. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob01095a · Cited by 24
Hirai, T., Nemoto, A., Ito, Y., & Matsuura, M. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05615-4 · Cited by 24
Dwyer, A. R., Kerkvliet, C. J. P., Krutilina, R. I., Playa, H. C., Parke, D. N., Thomas, W. A., Smeester, B. A., Moriarity, B. S., Seagroves, T. N., & Lange, C. A. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0295 · Cited by 24
An MRI-guided targeting dual-responsive drug delivery system for liver cancer therapy
Yao, W., Liu, C., Wang, N., Zhou, H., Chen, H., & Qiao, W. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.06.151 · Cited by 24
The development of PARP as a successful target for cancer therapy
Ferrara, R., Simionato, F., Ciccarese, C., Grego, E., Cingarlini, S., Iacovelli, R., Bria, E., Tortora, G., & Melisi, D. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1419870 · Cited by 25
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer
Michalak, E. M., & Jonkers, J. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9199-z · Cited by 23
Racial disparities in breast cancer preclinical and clinical models
Clarke, S., Chin, S. N., Dodds, L. V., George, S. H. L., & Badal, S. A. M. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01551-x · Cited by 23
Haanpää, M. K., Pylkäs, K., Moilanen, J. S., & Winqvist, R. (2013) · BMC Medical Genetics · doi:10.1186/1471-2350-14-82 · Cited by 23
Liu, X., Ran, R., Shao, B., Rugo, H. S., Yang, Y., Hu, Z., Wei, Z., Fengling, W., Kong, W., Song, G., et al. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.03.04 · Cited by 23
Delving into PARP inhibition from bench to bedside and back
Grignani, G., Merlini, A., Sangiolo, D., D’Ambrosio, L., & Pignochino, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107446 · Cited by 23
Beyond Genetics: Metastasis as an Adaptive Response in Breast Cancer
Ruscitto, F., Roda, N., Priami, C., Migliaccio, E., & Pelicci, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116271 · Cited by 23
Newer therapies for the treatment of metastatic breast cancer: A clinical update
Ponnusankar, S., & Mohan, A. (2013) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.117396 · Cited by 23
Advances in Small-Molecule Drug Discovery for Triple-Negative Breast Cancer
Fosu-Mensah, N., Peris, M. S., Weeks, H. P., Cai, J., & Westwell, A. D. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.129 · Cited by 23
Shawky, H., & Galal, S. (2014) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2014.10.002 · Cited by 22
Schwarzlose-Schwarck, S., Scholz, C. W., Regierer, A. C., Martus, P., Neumann, C., Habbel, P., Liu, H., Zang, C., Schefe, J.-H., Schulz, C., et al. (2012) · PubMed · Cited by 22
Current approaches to the management of Her2-negative metastatic breast cancer
Gogineni, K., & DeMichele, A. M. (2012) · Breast Cancer Research · doi:10.1186/bcr3064 · Cited by 22
Blakeley, J. O., Grossman, S. A., Chi, A. S., Mikkelsen, T., Rosenfeld, M. R., Ahluwalia, M. S., Nabors, B., Eichler, A. F., Ribas, I. G., Desideri, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0110 · Cited by 22
O-nitrobenzyl liposomes with dual-responsive release capabilities for drug delivery
Yao, W., Liu, C., Wang, N., Zhou, H., Shafiq, F., Yu, S., & Qiao, W. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.116016 · Cited by 22
Upreti, M., Jyoti, A., Johnson, S. E., Swindell, E. P., Napier, D., Sethi, P., Chan, R., Feddock, J. M., Weiss, H. L., O’Halloran, T. V., et al. (2106) · Oncotarget · doi:10.18632/oncotarget.9490 · Cited by 21
“An improved understanding of the biology of TNBC has led to the discovery of therapeutic targets for TNBC, such as the Notch signaling pathway (RO-4929097) [10], Wnt/b-catenin pathway (Salinomycin) [11], DNA repair pathways (PARP1 inhibitors: Iniparib, Olaparib) [12, 13], Overexpressed epidermal growth factor (EGFR in…”
BackgroundAdjuvant systemic treatment for individual patients with triple negative breast cancer
Oakman, C. A., Moretti, E., Galardi, F., Biagioni, C., Santarpia, L., Biganzoli, L., & Leo, A. D. (2011) · The Breast · doi:10.1016/s0960-9776(11)70311-3 · Cited by 21
K, K., Chau, W., Wong, C., Wong, K., Fung, N., Lee, A. J. T., Choi, C. L. Y., Suen, D. T. K., & Kwong, A. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.5.2109 · Cited by 21
Breast Cancer: A Molecular and Redox Snapshot
Raman, D., Foo, C. H. J., Clement, M., & Pervaiz, S. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6546 · Cited by 21
Resistance to Targeted Therapies in Breast Cancer
Braga, S. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3347-1_8 · Cited by 21
Supervised Machine Learning Predictive Analytics For Triple-Negative Breast Cancer Death Outcomes
Xu, Y., Ju, L.-S., Tong, J., Zhou, C.-M., & Yang, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s223603 · Cited by 21
Gu, L., Du, N., Jin, Q., Li, S., Xie, L., Mo, J., Shen, Z., Mao, D., Ji, J., Khadaroo, P. A., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102888 · Cited by 21
Bahamin, N., Ahmadian, S., Rafieian‐Kopaei, M., Mobini, G. R., Shafiezadeh, M., & Soltani, A. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5517944 · Cited by 21
Wang, Y., Chen, W., Shi, Y., Yan, C., Kong, Z., Wang, Y., Wang, Y., & Ma, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719623 · Cited by 21
Franchina, T., Adamo, B., Ricciardi, G. R. R., Caristi, N., Agostino, R. M., Proto, C., & Adamo, V. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19593 · Cited by 21
Breast cancer stem-like cells: Clinical implications and therapeutic strategies
Tudoran, O. M., Bălăcescu, O., & Berindan‐Neagoe, I. (2015) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-559 · Cited by 21
Baghi, N., Bakhshinejad, B., Keshavarz, R., Babashah, S., & Sadeghizadeh, M. (2018) · Gene · doi:10.1016/j.gene.2018.05.025 · Cited by 21
miR‑31‑5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC
Shen, X., Lei, J., & Du, L. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8191 · Cited by 20
Genta, S., Martorana, F., Stathis, A., & Colombo, I. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103539 · Cited by 20
Shibata, H., Miuma, S., Saldivar, J. C., & Huebner, K. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02016.x · Cited by 20
Should Triple-Negative Breast Cancer (TNBC) Subtype Affect Local-Regional Therapy Decision Making?
Moran, M. S. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e32 · Cited by 20
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
Thigpen, J. T. (2011) · Yearbook of Medicine · doi:10.1016/s0084-3873(11)00185-4 · Cited by 20
PARP inhibitors as precision medicine for cancer treatment
Du, Y., Yamaguchi, H., Hsu, J. L., & Hung, M. (2017) · National Science Review · doi:10.1093/nsr/nwx027 · Cited by 20
Chen, H., Lu, W., Zhang, Y., Zhu, X., Zhou, J., & Chen, Y. (2018) · Cancer Medicine · doi:10.1002/cam4.1892 · Cited by 20
Ozretić, L., Rhiem, K., Huss, S., Wappenschmidt, B., Markiefka, B., Sinn, H., Schmutzler, R. K., & Buettner, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1988 · Cited by 20
Iniparib in Metastatic Triple-Negative Breast Cancer
Domagała, P., Lubiński, J., & Domagała, W. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1101855 · Cited by 20
Liu, H., Qiu, H., Song, Y., Liu, Y., Wang, H., Lu, M., Deng, M., Gu, Y., Yin, J., Luo, K., et al. (2017) · Oncogene · doi:10.1038/onc.2016.355 · Cited by 19
Yin, Z.-X., Hang, W., Liu, G., Wang, Y.-S., Shen, X.-F., Sun, Q.-H., Li, D.-D., Jian, Y.-P., Zhang, Y.-H., Quan, C.-S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.21277 · Cited by 19
Phan, Z., Ford, C. E., & Caldon, C. E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106927 · Cited by 19
PARP inhibitors in cancer: moving beyond BRCA
Telli, M. L. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70236-4 · Cited by 19
Chemotherapy Plus Radiation in Advanced-Stage Endometrial Cancer
Schwandt, A., Chen, W. C.-Y., Martra, F., Zola, P., Debernardo, R., & Kunos, C. A. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31822b6594 · Cited by 19
Zhai, L., Li, S., Li, X., Li, H., Gu, F., Guo, X., Liu, F., Zhang, X., & Fu, L. (2014) · Pathology - Research and Practice · doi:10.1016/j.prp.2014.11.004 · Cited by 19
ADP-Ribosylated Proteins as Old and New Drug Targets for Anticancer Therapy: The Example of ARF6
Dani, N., Barbosa, A. J. M., Río, A. D., & Girolamo, M. D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804581882 · Cited by 19
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
Blum, J. L., Gonçalvès, A., Efrat, N., Debled, M., Conte, P., Richards, P. D., Richards, D., Lardelli, P., Nieto, A., Cullell-Young, M., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3675-x · Cited by 19
Smith, N. Z. (2012) · Clinical journal of oncology nursing · doi:10.1188/12.cjon.e33-e43 · Cited by 19
Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts
Denkert, C., Sinn, B. V., Issa, Y., Müller, B. M., Maisch, A., Untch, M., von Minckwitz, G., & Loibl, S. (2011) · Breast Care · doi:10.1159/000331696 · Cited by 19
Stuijver, D. J. F., Romualdi, E., van Zaane, B., Bax, L., Buller, H. R., Gerdes, V. E. A., & Squizzato, A. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1168-2 · Cited by 19
Dual Disruption of DNA Repair and Telomere Maintenance for the Treatment of Head and Neck Cancer
Lajud, S. A., Nagda, D. A., Yamashita, T., Zheng, J., Tanaka, N. K., Abuzeid, W. M., Civantos, A. M., Bezpalko, O., O'Malley, B. W., & Li, D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0176 · Cited by 19
The Potential of PARP Inhibitors in Neuro-Oncology
Carruthers, R., & Chalmers, A. J. (2012) · CNS Oncology · doi:10.2217/cns.12.13 · Cited by 19
Yang, K., Zeng, L., Ge, A., Bao, T., Xu, T., Xie, X., & Liu, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00825 · Cited by 19
Molecular pathways and molecular imaging in breast cancer: An update
Cervino, A. R., Burei, M., Mansi, L., & Evangelista, L. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.03.002 · Cited by 19
Chionh, F. J. M., Mitchell, G., Lindeman, G. J., Friedlander, M. L., & Scott, C. L. (2011) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2011.01430.x · Cited by 18
PARP Inhibitors in Lung Cancer
Spigel, D. R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826df1eb · Cited by 18
Development of PARP inhibitors in gynecological malignancies
Ang, Y. L. E., & Tan, D. S. P. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.02.008 · Cited by 18
Application of the concept synthetic lethality toward anticancer therapy: A promise fulfilled?
Canaani, D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.019 · Cited by 18
Recent Developments in Treatment Stratification for Metastatic Breast Cancer
Barton, S. R., & Swanton, C. (2011) · Drugs · doi:10.2165/11594480-000000000-00000 · Cited by 18
Emerging strategies to target the dysfunctional cohesin complex in cancer
Mintzas, K., & Heuser, M. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1609943 · Cited by 18
Dieras, V. C., Bonnefoi, H. R., Alba, E., Awada, A. H., Coudert, B. P., Pivot, X. B., Gligorov, J., Jager, A., Zambelli, S., Lindeman, G. J., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05305-w · Cited by 18
Li, C., Li, X., Li, G., Sun, L., Zhang, W., Jiang, J. T., & Ge, Q. (2020) · Oncology Reports · doi:10.3892/or.2020.7657 · Cited by 18
Causality in medicine with particular reference to the viral causation of cancers
Clarke, B. (2011) · PhilPapers (PhilPapers Foundation) · Cited by 18
Fremd, C., Jaeger, D., & Schneeweiß, A. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1537785 · Cited by 18
Targeted Treatment of Metastatic Triple‐Negative Breast Cancer: A Systematic Review
Madsen, A. M. H., Eefsen, R. L., Nielsen, D. L., & Kümler, I. (2024) · The Breast Journal · doi:10.1155/2024/9083055 · Cited by 17
Hiller, D. J., & Chu, Q. D. (2011) · International Journal of Breast Cancer · doi:10.1155/2012/829315 · Cited by 17
Miyagawa, Y., Matsushita, Y., Suzuki, H., Komatsu, M., Yoshimaru, T., Kimura, R., Yanai, A., Honda, J., Tangoku, A., Sasa, M., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4301 · Cited by 17
An overview of drug development for metastatic breast cancer
Stebbing, J., & Ellis, P. (2012) · British Journal of Nursing · doi:10.12968/bjon.2012.21.sup4.s18 · Cited by 17
Breuer, E.-K. Y., & Murph, M. M. (2011) · International Journal of Proteomics · doi:10.1155/2011/373584 · Cited by 17
Accelerated Approval for Pertuzumab in the Neoadjuvant Setting: Winds of Change?
Esserman, L. J., & DeMichele, A. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3131 · Cited by 17
Comparison of Cantharidin Toxicity in Breast Cancer Cells to Two Common Chemotherapeutics
Kern, K. M., & Schroeder, J. R. (2014) · International Journal of Breast Cancer · doi:10.1155/2014/423059 · Cited by 17
Gao, W., Zhang, J., Wang, W., Liu, Z., Chen, M., Hu, X., Zeng, L., Zheng, C., Song, H., & Zhang, Q. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121775 · Cited by 17
Parekh, T., Dodwell, D. J., Sharma, N., & Shaaban, A. M. (2015) · Pathobiology · doi:10.1159/000433582 · Cited by 17
Wang, J., Yang, X., Han, H., Wang, L., Bao, W., Wang, S., Hoffman, R. M., Yang, M., Qi, H., An, C., et al. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.01.12 · Cited by 17
Liu, F., Xie, B., Ye, R., Xie, Y., Zhong, B., Zhu, J., Tang, Y., Lin, Z., Tang, H., Wu, Z., et al. (2023) · Oncogenesis · doi:10.1038/s41389-023-00453-7 · Cited by 16
Aiad, H. A. S., Kandil, M. A., El-Tahmody, M. A., Abulkheir, I. L. H., Abulkasem, F. M., Elmansori, A. A., & Aleskandarany, M. A. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000124 · Cited by 16
Ran, W., Liu, X., Chang, L., Cai, Y., Zheng, C., Liu, J., Li, Y., & Zhang, P. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.027 · Cited by 16
Gao, X., Sun, B., Hou, Y., Liu, L., Sun, J., Xu, F., Li, D., & Hu, X. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2096020 · Cited by 16
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
Cristofanilli, M. (2012) · Journal of Oncology · doi:10.1155/2012/703858 · Cited by 16
Actualización del cáncer de mama en Atención Primaria (II/V)
Brusint, B., Vich-Pérez, P., Álvarez-Hernández, C. F., Cuadrado-Rouco, C., Diaz-Garcia, N., & Redondo-Margüello, E. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.03.003 · Cited by 16
Qiao, W., Pan, L., Kou, C., Li, K., & Yang, M. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172413 · Cited by 16
Roles of p53 and p16 in triple-negative breast cancer
Dang, D. N., & Peng, Y. S. (2013) · Breast Cancer Management · doi:10.2217/bmt.13.59 · Cited by 16
DNA Repair Pathways and their Therapeutic Potential in Lung Cancer
Burgess, J. T., Croft, L. V., Wallace, N. C., Stephenson, S., Adams, M. N., Ashton, N. W., Solomon, B., O'Byrne, K. J., & Richard, D. J. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.12 · Cited by 15
Wu, W., Zhu, H., Liang, Y., Kong, Z., Duan, X., Li, S., Zhao, Z., Yang, D. K., & Zeng, G. (2014) · International Urology and Nephrology · doi:10.1007/s11255-014-0642-0 · Cited by 15
Ge, L., Tang, Y., Zhang, Q., Tian, J., Wang, X., Pieper, D., Pan, B., Li, L., Ling, J., Bing, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19102 · Cited by 15
Vastrad, B. M., Vastrad, C. M., Tengli, A., & Iliger, S. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4562-y · Cited by 15
Rinnerthaler, G., Gampenrieder, S. P., Petzer, A. L., Burgstaller, S., Fuchs, D., Rossmann, D. H., Balić, M., Egle, D., Rumpold, H. F., Singer, C. F., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4979-0 · Cited by 15
Emerging Roles of Long Noncoding RNA Regulator of Reprogramming in Cancer Treatment
Sun, D.-E., & Ye, S.-Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s253042 · Cited by 15
Metadata
- Authors
- O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C.
- Affiliations
- Texas Oncology (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-20
- Volume
- 364
- Issue
- 3
- Pages
- 205-214
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2111429259
- Cited by
- 817
- References
- 32
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 22 · 2022: 23 · 2021: 30 · 2020: 27 · 2019: 30 · 2018: 47 · 2017: 52 · 2016: 42 · 2015: 72 · 2014: 90 · 2013: 94 · 2012: 133
- FWCI
- 70.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- metastatic triple-negative breast cancer, PARP inhibition, gemcitabine, carboplatin, combination chemotherapy, DNA repair deficiency, clinical benefit, progression-free survival, overall survival, adverse events, neutropenia, thrombocytopenia, drug safety and efficacy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Gemcitabine, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Deoxycytidine, Female, Humans, Neoplasm Metastasis, Survival Analysis, Carboplatin, Cross-Over Studies, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.